Aprea Therapeutics (APRE) Institutional Ownership $1.93 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$1.95 +0.02 (+1.24%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Aprea Therapeutics (NASDAQ:APRE)CurrentInstitutional OwnershipPercentage34.19%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$854.84KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$297.77K Get APRE Insider Trade Alerts Want to know when executives and insiders are buying or selling Aprea Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data APRE Institutional Buying and Selling by Quarter Aprea Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025Exome Asset Management LLC28,972$59K0.1%-77.4%0.524% 5/14/2025Stonepine Capital Management LLC102,242$209K0.2%-31.5%1.851% 2/17/2025Stonepine Capital Management LLC149,221$491K0.4%+8.8%2.748% 2/17/2025BNP Paribas Financial Markets13,011$43K0.0%N/A0.240% 2/12/2025Landscape Capital Management L.L.C.35,328$116K0.0%N/A0.651% 2/11/2025LPL Financial LLC16,052$53K0.0%N/A0.296% 8/21/2024Stonepine Capital Management LLC137,174$558K0.5%N/A2.526% 8/9/2024Dimensional Fund Advisors LP11,071$45K0.0%N/A0.204% 5/15/2023AIGH Capital Management LLC345,000$1.53M0.6%N/A9.244% 5/15/2023Sio Capital Management LLC280,000$1.24M0.6%N/A7.503% Get the Latest News and Ratings for APRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/12/2022Gyon Technologies Capital Management LP20,570$38K0.0%N/A0.094% 5/12/2022 Magnus Financial Group LLC14,856$28K0.0%-56.3%0.068% 2/15/2022Kennedy Capital Management Inc.336,730$966K0.0%-1.7%1.569% 2/14/2022PDT Partners LLC142,600$409K0.0%+62.5%0.664% 2/10/2022 Magnus Financial Group LLC33,981$98K0.0%N/A0.158% 11/16/2021Verition Fund Management LLC20,101$103K0.0%N/A0.094% 11/12/2021Geode Capital Management LLC198,339$1.01M0.0%+89.9%0.936% 11/10/2021Goldman Sachs Group Inc.144,758$740K0.0%+131.4%0.683% 11/9/2021BlackRock Inc.354,275$1.81M0.0%-0.9%1.672% 9/17/2021Virtu Financial LLC41,142$201K0.0%+292.9%0.194% 8/17/2021Walleye Capital LLC98,931$483K0.0%-16.5%0.467% 8/17/2021Walleye Trading LLC27,455$134K0.0%-33.4%0.130% 8/16/2021PDT Partners LLC124,234$606K0.0%N/A0.586% 8/16/2021Morgan Stanley1,019,776$4.98M0.0%+2.2%4.813% 8/16/2021Kennedy Capital Management Inc.353,926$1.73M0.0%+575.2%1.670% 8/16/2021Charles Schwab Investment Management Inc.50,366$246K0.0%-26.5%0.238% 8/16/2021State Street Corp40,832$199K0.0%-67.2%0.193% 8/16/2021Goldman Sachs Group Inc.62,546$305K0.0%-14.4%0.295% 8/13/2021Northern Trust Corp32,530$159K0.0%-69.2%0.154% 8/13/2021Geode Capital Management LLC104,447$509K0.0%-35.2%0.493% 8/13/2021Vanguard Group Inc.707,422$3.45M0.0%-6.0%3.339% 8/12/2021SG Americas Securities LLC598,395$2.92M0.0%-8.8%2.824% 8/12/2021JPMorgan Chase & Co.60,315$294K0.0%+264.4%0.285% 8/12/2021Ergoteles LLC18,570$91K0.0%N/A0.088% 8/11/2021Great Lakes Advisors LLC17,895$87K0.0%N/A0.084% 8/11/2021Bank of New York Mellon Corp16,843$83K0.0%-64.8%0.079% 5/19/2021Virtu Financial LLC10,471$53K0.0%-56.4%0.049% 5/18/2021Voloridge Investment Management LLC304,198$1.55M0.0%N/A1.436% 5/18/2021Morgan Stanley998,127$5.09M0.0%+111.0%4.711% 5/17/2021Royal Bank of Canada15,173$76K0.0%+76.5%0.072% HIDDEN IN THE BOOK OF GENESIS… (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code5/17/2021HRT Financial LP73,587$375K0.0%N/A0.347% 5/17/2021Nuveen Asset Management LLC17,565$90K0.0%-48.7%0.083% 5/17/2021Goldman Sachs Group Inc.73,107$373K0.0%N/A0.345% 5/14/2021UBS Asset Management Americas Inc.22,700$116K0.0%N/A0.107% 5/13/2021Bank of New York Mellon Corp47,783$244K0.0%+57.5%0.226% 5/12/2021Northern Trust Corp105,719$539K0.0%-6.8%0.499% 5/12/2021Geode Capital Management LLC161,147$821K0.0%+9.1%0.761% 5/12/2021JPMorgan Chase & Co.16,550$85K0.0%+380.3%0.078% (Data available from 1/1/2016 forward) APRE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of APRE shares? During the previous two years, the following institutional investors and hedge funds held shares of Aprea Therapeutics shares: Stonepine Capital Management LLC ($209K), Landscape Capital Management L.L.C. ($116K), Exome Asset Management LLC ($59K), LPL Financial LLC ($53K), and Dimensional Fund Advisors LP ($45K), BNP Paribas Financial Markets ($43K).Learn more on Aprea Therapeutics' institutional investors. What percentage of Aprea Therapeutics' stock is owned by institutional investors? 34.19% of Aprea Therapeutics' stock is owned by institutional investors. Learn more on APRE's institutional investor holdings. Which institutional investors have been buying Aprea Therapeutics' stock? The following institutional investors have purchased Aprea Therapeutics' stock in the last 24 months: Stonepine Capital Management LLC ($149.22K), Landscape Capital Management L.L.C. ($35.33K), LPL Financial LLC ($16.05K), BNP Paribas Financial Markets ($13.01K), and Dimensional Fund Advisors LP ($11.07K). How much institutional buying is happening at Aprea Therapeutics? Institutional investors have bought a total of 224,683 shares in the last 24 months. This purchase volume represents approximately $854.84K in transactions. Which of Aprea Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Aprea Therapeutics stock in the last 24 months: Exome Asset Management LLC ($98.99K), and Stonepine Capital Management LLC ($46.98K). How much institutional selling is happening at Aprea Therapeutics? Institutional investors have sold a total of 145,967 shares in the last 24 months. This volume of shares sold represents approximately $297.77K in transactions. Related Companies ITRM Institutional Ownership KPTI Institutional Ownership SNYR Institutional Ownership KZR Institutional Ownership CLNN Institutional Ownership OKUR Institutional Ownership FGEN Institutional Ownership MIRA Institutional Ownership ESLA Institutional Ownership DYAI Institutional Ownership This page (NASDAQ:APRE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
